- Title: Subtitle
- A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS)
- Creators
- George D. Demetri - Dana-Farber Brigham Cancer CenterMargaret von Mehren - Temple University Health SystemRobin Lewis Jones - Seattle Cancer Care AllianceMartee Leigh Hensley - Memorial Sloan Kettering Cancer CenterScott Schuetze - University of Michigan–Ann ArborArthur P. Staddon - University of PennsylvaniaMohammed M. Milhem - University of IowaAnthony D. Elias - University of Colorado Cancer CenterKristen N. Ganjoo - Stanford UniversityHussein Abdul-Hassan Tawbi - UPMC Hillman Cancer CenterBrian Andrew Van Tine - Washington University in St. LouisAlexander I. Spira - Virginia Cancer SpecialistsAndrew Peter Dean - St John of God Subiaco HospitalNushmia Z. KhokharYoun Choi ParkRoland Elmar KnoblauchTrilok V. ParekhRobert G. Maki - Icahn School of Medicine at Mount SinaiShreyaskumar Patel - The University of Texas MD Anderson Cancer Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.33(15_suppl), pp.10503-10503
- DOI
- 10.1200/jco.2015.33.15_suppl.10503
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363297302771
Abstract
A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS)
Journal of clinical oncology, Vol.33(15_suppl), pp.10503-10503
05/20/2015
DOI: 10.1200/jco.2015.33.15_suppl.10503
Details
Metrics
10 Record Views